Ionis Pharmaceuticals (NASDAQ: IONS) Director Joseph Klein III sold 11,518 shares of the company's common stock on July 1, 2026, for a total value of approximately $910,416. The sales were executed under a pre-arranged Rule 10b5-1 trading plan, which was adopted by Mr. Klein on November 25, 2025.
The shares were sold in multiple transactions at prices ranging from $78.39 to $79.45 per share. The timing of Klein's sale comes as Ionis stock has delivered a remarkable 93.44% return over the past year and is currently trading near its 52-week high of $86.74, according to InvestingPro data. The stock is currently considered overvalued based on InvestingPro's Fair Value analysis, placing it among companies on the Most Overvalued list. InvestingPro offers 9 additional exclusive tips about IONS, along with comprehensive financial metrics to help investors make informed decisions.
Prior to these sales, Mr. Klein exercised non-qualified stock options to acquire 11,518 shares of Ionis Pharmaceuticals common stock at an exercise price of $39.94 per share, totaling $460,028.
Additionally, Mr. Klein received new equity awards on July 1, 2026. These included a grant of 5,369 non-qualified stock options with an exercise price of $79.19, and 2,301 restricted stock units (RSUs). These grants were adjusted downward in accordance with the company's Non-Employee Director Compensation Policy, ensuring annual equity compensation in 2026 does not exceed $400,000 based on the aggregate grant date fair value. The stock options are scheduled to vest 100% on the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier. The Restricted Stock Units also vest 100% on the first anniversary or next annual meeting, with delivery of shares deferred until the earlier of Mr. Klein's separation from service or a change in control of the company. Each RSU represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
Following these transactions, Mr. Klein directly holds 11,014 shares of common stock. He also indirectly holds 200 shares through his son, though he disclaims beneficial ownership of these securities.
In other recent news, Ionis Pharmaceuticals announced the completion of participant enrollment for its Phase 3 REVEAL study of obudanersen in patients with Angelman syndrome. The study enrolled 136 participants aged 2 to under 18 years old, with topline data expected in the second half of 2027. In addition, the U.S. Food and Drug Administration has granted approval for Ionis's drug TRYNGOLZA (olezarsen) to treat severe hypertriglyceridemia. This approval, issued under Priority Review, allows the drug to be used as an adjunct to diet for reducing triglycerides and the risk of acute pancreatitis in adults. TRYNGOLZA is available in two dosages and is administered monthly via autoinjector. Following the approval, Needham reiterated a Buy rating for Ionis, maintaining a price target of $105. H.C. Wainwright also raised its price target for Ionis to $130, while Oppenheimer reiterated an Outperform rating with a $110 price target. These developments reflect positive sentiment from analysts regarding Ionis's recent regulatory success.